Skip to main content

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Publication ,  Journal Article
Vredenburgh, JJ; Desjardins, A; Herndon, JE; Dowell, JM; Reardon, DA; Quinn, JA; Rich, JN; Sathornsumetee, S; Gururangan, S; Wagner, M ...
Published in: Clin Cancer Res
February 15, 2007

PURPOSE: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements in survival seen following currently available salvage therapy. This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizumab, and a cytotoxic agent, irinotecan, is safe and effective for patients with recurrent grade III-IV glioma. EXPERIMENTAL DESIGN: We conducted a phase II trial of bevacizumab and irinotecan in adults with recurrent grade III-IV glioma. Patients with evidence of intracranial hemorrhage on initial brain magnetic resonance imaging were excluded. Patients were scheduled to receive bevacizumab and irinotecan i.v. every 2 weeks of a 6-week cycle. Bevacizumab was administered at 10 mg/kg. The dose of irinotecan was determined based on antiepileptic use: patients taking enzyme-inducing antiepileptic drugs received 340 mg/m(2), whereas patients not taking enzyme-inducing antiepileptic drugs received 125 mg/m(2). Toxicity and response were assessed. RESULTS: Thirty-two patients were assessed (23 with grade IV glioma and 9 with grade III glioma). Radiographic responses were noted in 63% (20 of 32) of patients (14 of 23 grade IV patients and 6 of 9 grade III patients). The median progression-free survival was 23 weeks for all patients (95% confidence interval, 15-30 weeks; 20 weeks for grade IV patients and 30 weeks for grade III patients). The 6-month progression-free survival probability was 38% and the 6-month overall survival probability was 72%. No central nervous system hemorrhages occurred, but three patients developed deep venous thromboses or pulmonary emboli, and one patient had an arterial ischemic stroke. CONCLUSIONS: The combination of bevacizumab and irinotecan is an active regimen for recurrent grade III-IV glioma with acceptable toxicity.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

ISSN

1078-0432

Publication Date

February 15, 2007

Volume

13

Issue

4

Start / End Page

1253 / 1259

Location

United States

Related Subject Headings

  • Prospective Studies
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Irinotecan
  • Humans
  • Glioma
  • Female
  • Camptothecin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., … Friedman, H. S. (2007). Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res, 13(4), 1253–1259. https://doi.org/10.1158/1078-0432.CCR-06-2309
Vredenburgh, James J., Annick Desjardins, James E. Herndon, Jeannette M. Dowell, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, et al. “Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.Clin Cancer Res 13, no. 4 (February 15, 2007): 1253–59. https://doi.org/10.1158/1078-0432.CCR-06-2309.
Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007 Feb 15;13(4):1253–9.
Vredenburgh, James J., et al. “Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.Clin Cancer Res, vol. 13, no. 4, Feb. 2007, pp. 1253–59. Pubmed, doi:10.1158/1078-0432.CCR-06-2309.
Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007 Feb 15;13(4):1253–1259.

Published In

Clin Cancer Res

DOI

ISSN

1078-0432

Publication Date

February 15, 2007

Volume

13

Issue

4

Start / End Page

1253 / 1259

Location

United States

Related Subject Headings

  • Prospective Studies
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Irinotecan
  • Humans
  • Glioma
  • Female
  • Camptothecin